Other firms spray the landscape with fire retardant and cocoon trees and bushes in thick fireproof materials, according to the LA Times. But as these companies rack up cash, the ones who hire them ...

The U.S. government has handed Moderna almost $600 million to accelerate its work on various bird flu vaccines as well as work on mRNA vaccines for other influenza strains with pandemic potential.

A bad seven-month stretch just got worse for Moderna (NASDAQ: MRNA). The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.

Moderna made a lot of money during the pandemic, but its post-pandemic prospects look bleak. Sales in 2025 could be down more than half from 2024 levels, according to Moderna's latest guidance ...

Moderna fell to a new 52-week low after some disappointing news. The short explanation is that demand for Moderna's COVID-19 vaccine has plunged since the end of the pandemic. Moderna still has ...

Moderna's (NASDAQ: MRNA) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's shares plunged 21.2% through 10:20 a.m. ET Monday after it updated ...

NOAA has declared that a La Niña is underway. This cool weather event is likely to be shorter and weaker than usual, but will still affect global weather and climate. When you purchase through ...

There have been 67 confirmed human bird flu cases in the U.S. since April 2024. Moderna has been awarded approximately $590 million from the federal government to help speed up the development of ...

Earlier this month, Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s lackluster vaccine sales in COVID-19 and respiratory ...

Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by $1 billion. The stock broke down from a two ...

Moderna projects $1.5 billion-$2.5 billion in 2025 revenue, with cash and investments estimated at $6 billion by year-end. 2024 product sales are approximately $3 billion-$3.1 billion, driven by $ ...

There are currently three vaccine candidates moving through the clinical pipeline in human trials right now, and the furthest along is Moderna, which has developed a norovirus vaccine with the ...